<DOC>
	<DOCNO>NCT02858206</DOCNO>
	<brief_summary>This prospective , non-randomized phase II study aim compare radiotherapy concurrent nimotuzumab concurrent chemoradiotherapy obtain non-inferior pCR rate pathological lymph node metastasis rate premise low toxicity locally advanced esophageal cancer .</brief_summary>
	<brief_title>Simultaneous Integrated Boost Radiotherapy Concurrent Nimotuzumab Chemotherapy Esophageal Carcinoma</brief_title>
	<detailed_description>In era IMRT concurrent chemoradiotherapy , 5-year overall survival esophageal cancer increase 10 % 20 % -40 % , recurrence rate decrease 80 % 50 % -60 % , local recurrence remain important type failure . What call enhance local control without increase toxicity improve survival . The investigator find effective safe regimen simultaneously integrate boost radiotherapy previous study , achieve high dose tumor area avoid normal tissue . However , recent prospective study report neoadjuvant chemoradiotherapy result much high toxicity compare neoadjuvant chemotherapy ( 46 % vs. 15 % , p= 0.04 ) . Although chemoradiotherapy reach high pCR rate ( 28 % vs. 9 % , p=0.002 ) , patient differ survival two group . Nimotuzumab humanize monoclonal antibody EGFR . Radiotherapy combine Nimotuzumab reveals synergistic effect head neck cancer low toxicity compare concurrent chemoradiotherapy . Our previous study show EGFR expression rate similar esophageal cancer head neck cancer . Based result , investigator design study aim obtain non-inferior pCR rate pathological lymph node metastasis rate premise low toxicity .</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Polystyrene sulfonic acid</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Nedaplatin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Diagnosis clinical stage T14aN01M1a untreated squamous esophageal carcinoma KPSâ‰¥70 Adequate organ function No known history drug allergy Known drug allergy Insufficient hepatorenal function Severe cardiovascular disease , diabetes uncontrolled blood sugar , mental disorder , uncontrolled severe infection , active ulceration need intervention .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Locally advanced esophageal cancer</keyword>
	<keyword>Radiotherapy nimotuzumab</keyword>
	<keyword>Concurrent chemoradiotherapy</keyword>
</DOC>